36 results about "FBG - Fasting blood glucose" patented technology

The invention provides a method for establishing a type 2 diabetes animal model. An animal is fed with a high-fat and high-sugar feed for a period of time, and the animal is drenched with alcohol with certain concentration at the same time. The attack process of human type 2 diabetes is simulated in the method; and the prepared animal model has typical characteristics of the type 2 diabetes such as high fasting blood glucose, high insulinemia, hyperlipidemia and impaired glucose tolerance, and is suitable for mechanism research of the type 2 diabetes and screening of a large quantity of medicaments.

The invention discloses a moringa leaf extract with blood sugar lowering activity and a preparation method thereof. The preparation method comprises the following steps: crushing and sieving, performing alkali treatment, performing protease enzymolysis, performing cellulase enzymolysis, performing high-pressure homogenization, performing high-temperature extraction, performing low-temperature high-speed centrifugation, performing ultrafiltration separation and concentration, performing protease enzymolysis, performing low-temperature high-speed centrifugation, performing secondary ultrafiltration separation and concentration, performing freeze drying and the like to obtain the moringa leaf extract with the blood sugar lowering activity. The extract has the polysaccharide content of 30% orabove; an animal experimental model of a type-2 diabetic rat verifies that the extract has good blood sugar lowering activity and can effectively reduce the fasting blood glucose of the type-2 diabetic rat and enhance the oral glucose tolerance dosage thereof; the acting effect of the extract is similar to that of metformin with the same dosage. An extracting technology is simple, the whole technological process can meet a food-grade requirement, and the moringa leaf extract can be applied to the field of medicines, health-care products, food and the like.

The invention discloses a method and device for predicting a future blood glucose value and computer equipment, and relates to the technical field of computers, capable of effectively solving the problem that in the prior art, only the current blood glucose value of a user can be judged, but the future blood glucose value of the user cannot be predicted. The method comprises the following steps: extracting sample user data corresponding to a sample user whose diabetes follow-up record is greater than a preset duration threshold from an original health record and an electronic medical record; utilizing the sample user data to create a prediction model of a blood glucose value time sequence; and inputting historical user data of a target user into the prediction model, and predicting a firstprediction sequence of fasting blood glucose values of the target user in a preset future time period and a second prediction sequence of blood glucose values of two hours after meal, wherein the historical duration corresponding to the historical user data is smaller than the preset duration threshold, and both the target user and the sample user are diabetic patients. The method and device forpredicting a future blood glucose value are suitable for predicting the future blood glucose value of the target user.

A method of controlling an insulin infusion device comprises operating a processor architecture comprising at least one processor device to calculate a maximum insulin infusion rate for the user based on a fasting blood glucose value associated with the user, a total daily insulin value associated with the user, and fasting insulin delivery data that is indicative of insulin delivered to the user during a fasting period, wherein the maximum insulin infusion rate is applicable during a period of closed-loop operation of the insulin infusion device; obtaining a first closed-loop insulin infusion rate for the user, wherein the first closed- loop insulin infusion rate is obtained for a current sampling point during the period of closed- loop operation; and providing a second closed-loop insulin infusion rate for the user when the obtained first closed-loop insulin infusion rate is greater than the calculated maximum insulin infusion rate, wherein the second closed-loop insulin infusion rate is less than the first closed-loop insulin infusion rate; the first closed-loop insulin infusion rate is calculated in accordance with a proportional-integral-derivative insulin feedback (PID-IFB) control algorithm; and inhibiting windup of an integral component of the PID-IFB control algorithm when the obtained first closed-loop insulin infusion rate is greater than the calculated maximum insulin infusion rate.

The invention relates to a self-screened Lactobacillus acidophilus SJLH001 (La SJLH001 for short) with probiotic function of regulating blood sugar and cholesterol level and application thereof in probiotic food. The strain has good tolerance to gastrointestinal environment, and has antioxidant, hydrophobic, ultrasonic resistance, reducing power and other in vitro benefits. In vitro and in vivo functional tests showed that La-SJLH001 has significant amylase inhibitory activity and alpha-Glucose glycerase inhibitory activity, and can significantly reduce fasting blood glucose, postprandial blood glucose level, enhance the tolerance of glucose, alleviate the pancreatic islet enlargement, reduce serum cholesterol level, enhance intestinal mucosal protection and other functions. La- SJLH001 has significant hypoglycemic and cholesterol-lowering activities, which makes it widely used in various forms of probiotic foods (such as probiotic tablet candy, probiotic solid drinks, etc.).

The invention discloses a preparation method of an OLETF rat fasting blood-glucose elevation model, belonging to animal zoological medicinal models and feeds specially used for specifically animals. In the invention, an OLETF rat is feed by high-fat feed in 6-8 weeks, and the high-fat feed comprises the following raw materials in percentage by weight: 60-65 percent of standard feed, 10-12 percentof yolk powder, 10-12 percent of lard, 8-12 percent of sugar-free full-cream powder, 2-14 percent of cane sugar and 1-2 percent of water. The OLETF rat fed by the feed can simulate the morbidity process of human type II diabetes more and is good for the research of the type II diabetes; and the invention also shortens the time the OLETF rat develops into the diabetes, accelerates the molding, saves the experimental period and reduces the experimental cost.

The invention discloses application of L-arabinose in preparing medicines or health-care products for preventing or treating metabolic syndrome, and in particular application of L-arabinose in preparing medicines or health-care products for simultaneously reducing total cholesterol, triglyceride, fasting blood-glucose, blood pressure, waistline and weight, blood uric acid and glutamic-pyruvic transaminase of human body. The applicant discovers that for adults, in a taking dosage range of 10-20g/person/day, total cholesterol, triglyceride, fasting blood-glucose, blood pressure, waistline and weight, blood uric acid and glutamic-pyruvic transaminase of human body can be simultaneously reduced clinically. Not only is functions of the body not damaged, but also digestion and absorption of proteins and vitamins are not affected while the indexes are simultaneously reduced, so that the purpose of improving the functions of the body and preventing and treating metabolic syndrome is realized.

A method for evaluating insulin resistance in a simple and highly reliable manner is provided. This method comprises measuring a fasting insulin parameter in blood, a fasting blood sugar parameter, and an adiponectin parameter and evaluating insulin resistance using, as an index, a value obtained by the following calculation formula (I):

(Fasting insulin value)×(Fasting blood sugar value)/Adiponectin value   (I)

The invention discloses a pharmaceutical use of protopanaxatriol or/and derivatives thereof as active ingredient(s) for preparing medicines for treating fatty liver. Research results show that the protopanaxatriol has an obvious in-vitro effect of inhibiting fat cell differentiation and also has the in-vivo effects of preventing the weight increase of high-fat meal induced fat rats, inhibiting the volume increase of body fat cells, improving fasting blood-glucose, insulin resistance and dyslipidemia and the like; in addition, PPAR gamma report gene analysis results indicate that the protopanaxatriol is capable of selectively inhibiting the transcriptional activity of PPAR gamma. In other words, the protopanaxatriol has remarkable treatment activity on the fatty liver, and also is capable of achieving the effect of preventing, improving and/or treating metabolic diseases such as obesity by selectively inhibiting the transcriptional activity of PPAR gamma, and has a remarkable pharmaceutical value especially for obesity patients suffering from fatty liver.

The invention provides an experiment analysis method for blood glucose reducing efficacy of Shenlian decoction rapidly disintegrating tablets for reducing blood glucose and belongs to the technical field of traditional Chinese medicine research. The method comprises the following steps of step one, selection of experiment grouping; step two, detection of physiological indicators, including detection of mice fasting blood-glucose, total cholesterol and triglyceride, detection of glucose tolerance, detection of urine volume, urine protein and urinary albumin, detection of serum creatinine and serum urea nitrogen, detection of serum sodium and serum potassium, detection of urine sodium and urine potassium and detection of weight and kidney indexes; step three, statistics of pathology; step four, analysis of statistical results; according to the experiment analysis method, an effective constituent ginseng total saponin and coptis total alkaloid compound (RH for short) of the Shenlian decoction rapidly disintegrating tablets for reducing blood glucose can effectively reduce the blood glucose level of a diabetic patient and has a certain therapeutic effects for early diabetic nephropathy.

The invention discloses a construction method of an animal experimental model for verifying a food blood glucose generation index and the animal model constructed through the method. The construction method comprises the steps that at least ten female rats and at least ten male rats are selected from wistar rats and SD rats, the rats are not fed on food and fed on water for 10 hours to 16 hours, and the intragastric administration food amount is calculated through weighing; the fasting blood glucose is detected by adopting a Roche glucometer, blood glucose values obtained 30 min, 60 min, 90 min and 120 min after intragastric administration of glucose, maltose, soft sugar, saccharose, lactose and fructose is conducted are detected, and the area under a food blood glucose response curve of all time detection points of each rat in each group is calculated by adopting an integral method; a glucose experiment result is taken as the GI standard 100, and GI values of other food are calculated according to the following formula: GI=100*the area under a blood glucose response curve of the food to be verified/the area of a blood glucose response curve of glucose; trend comparison is conducted on the sequence of the food GI values verified from the rats and the sequence of the GI values verified from a human body, and 7-10-week-age SD male rats with the weight of 210 g to 350 g are taken as the animal experimental model for verifying the food blood glucose generation index.

The invention belongs to the technical field of medicine, and provides the use of aucubin in preparing a medicine for treating type 2 diabetes. A mouse model of type 2 diabetes is established by intraperitoneal injection of streptozotocin after 4 weeks of a high-fat diet. Then, aucubin is injected intraperitoneally at low, medium and high doses for 4 weeks respectively, four items of body weight,fasting blood glucose, insulin and blood lipid of mice are detected, the insulin resistance index and insulin sensitivity index are calculated, and the morphological changes of islets in pancreas areobserved by HE staining. The results show that the levels of insulin, TG, T-CHO and LDL-C in the serum of the mouse model of type 2 diabetes can be reduced, the level of HDL-C can be increased, and the insulin resistance index and insulin sensitivity index can be improved by aucubin in low, medium, and high doses of groups, compared with the model group. The atrophy of islets in the pancreas of the model mouse of type 2 diabetes is also improved by aucubin which has a better protective effect on the pancreas.

The invention provides hawthorn health food assisting regulating blood sugar level. The hawthorn health food is formed by performing reasonable compounding on hawthorn alcohol extract and a water extract composition of corn stigma, siraitia grosvenorii and lycium barbarum, and specially comprises the following components in parts by weight: 50 to 100 parts of the hawthorn alcohol extract, and 10 to 50 parts of a water extract composition of the corn stigma, siraitia grosvenorii and lycium barbarum, wherein the water extract composition is prepared from the corn stigma, siraitia grosvenorii andlycium barbarum according to the mass ratio being (20-30): (5-10): (5-10). The hawthorn health food obviously reduce the fasting blood-glucose level, and compared with the prior art, the food has equivalent or better efficacy of assisting regulating blood sugar level, and produces the effect of synergistic interaction. Meanwhile, as all raw materials belongs to medicinal and edible materials, thefood has the characteristics of rice resources, wide distribution, low price and high availability, and the food is simple in production process, low in operation cost, more suitable for common consumer groups, and good in safety.

Provided is a composition for preventing, improving or treating obesity, which includes a Platycodon grandiflorum extract as an active ingredient and a method for preparing the extract with an improved anti-obesity effect. The extract shows an effect of inhibiting increases in body weight and fat mass caused by a high-fat diet for normalization, an increase in fasting blood glucose and a decrease in energy expenditure in a diet-induced obesity mouse model. Further, compared to an extract prepared by a conventional extraction method, the Platycodon grandiflorum extract shows a more excellent effect of inhibiting increases in body weight and fat mass, fasting blood glucose, and blood lipid and adipokine contents in experiments, resulting in an excellent anti-obesity effect. Therefore, the Platycodon grandiflorum extract prepared is expected to be useful for preventing obesity and treating obesity-related complications that can be caused by an increase in fat mass as well as obesity.

The invention discloses application of a curcumin derivative to preparation of medicines for resisting diabetes and complication thereof and in particular relates to application of (1E,6E)-1,7-di(3,5-ditertbutyl-4-hydroxyl phenyl)heptyl-1,6-diene-3,5-diketone to preparation of medicines, health-care products and food for preventing and treating diabetes and complication thereof. The (1E,6E)-1,7-di(3,5-ditertbutyl-4-hydroxyl phenyl)heptyl-1,6-diene-3,5-diketone can obviously reduce serum, liver triglyceride, total cholesterol and low-density lipoprotein of high fat feed and streptozotocin induced diabetes model mice, can reduce fasting blood glucose and glycated hemoglobin of the model mice, can improve glucose tolerance of the model mice, can obviously improve glycometabolism and lipid metabolism of the diabetes model mice, and can obviously reduce fatty degeneration of liver and aortic arch and lesion of atherosclerosis.

The invention discloses a microRNA sequence for early diagnosis of type 2 diabetes and an application of the microRNA sequence, and belongs to the technical field of medicine. The sequence is microRNA-X, the microRNA sequence is shown as SEQ:ID:NO:1, and the sequence of a design primer is shown as SEQ:ID:NO:2-SEQ:ID:NO:3. According to the invention, serum of 562 Uyghur individuals is collected, analysis is performed by using an Illumina Infinium Global Screening Array-24 v1.0 (GSA) Bead Chip technology, and the microRNA sequence significantly positively correlated with fasting blood glucose isfound.

The invention provides a preparation method of a bitter gourd health-caring food with an auxiliary blood-glucose-reducing effect. The bitter gourd health-caring food with the auxiliary blood-glucose-reducing effect is prepared by rationally compounding an alcohol extract of bitter gourds with a water extract composition of fructus momordicae, mulberry fruits, stigmata maydis and stevia; the bittergourd health-caring food specifically comprises the following ingredients in parts by weight: 60-70 parts of the alcohol extract of the bitter gourds, and 30-40 parts of the water extract compositionof the fructus momordicae, the mulberry fruits, the stigmata maydis and the stevia; and the water extract composition is prepared from the fructus momordicae, the mulberry fruits, the stigmata maydisand the stevia at mass ratio of (30-35) to (20-25) to (5-8) to (5-8). The bitter gourd health-caring food with the auxiliary blood-glucose-reducing effect is capable of significantly reducing fastingblood glucose; compared with the prior art, the bitter gourd health-caring food with the auxiliary blood-glucose-reducing effect has equivalent or better auxiliary blood-glucose-reducing effects, andproduces synergistic effects. In addition, the raw materials all have the characteristics of being rich in resources, wide in distribution, low in cost, easy to obtain and the like; and the production processes are relatively simple and relatively low in operation cost. Thus, the bitter gourd health-caring food with the auxiliary blood-glucose-reducing effect is more suitable for ordinary consumers and high in safety.

The invention provides application of a pharmaceutical composition to preparation of medicines for treating type 2 diabetes mellitus, and the pharmaceutical composition is prepared from the followingraw materials by a weight ratio: 2-10 parts of rhizoma coptidis and 1-10 parts of fructus evodiae. The composition provided by the invention can effectively improve the levels of fasting plasma glucose (FPG), fasting insulin (FINS) and OGTT2h plasma glucose (OGTT2hPG) in patients with the type 2 diabetes mellitus, and does not have an adverse effect; therefore, a new choice is provided for clinical medication.

The invention discloses a tea drink with effects of reducing blood glucose and proteinuria for sub-health population. The active ingredients of the tea drink are prepared from the following raw medicinal materials: corn stigma, hemp leaves, lophatherum gracile, lycium barbarum and liquorice. The tea drink disclosed by the invention has a certain effect of reducing blood glucose and proteinuria, but the reduction scale is not too large. Therefore, the tea drink is particularly applicable to the sub-health population having sustained fasting blood-glucose equivalent to a normal blood glucose value or slightly higher than the normal blood glucose value, and the blood glucose index of the sub-health population can be reduced from a high critical point to a normal range.